Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming FDA advisory committee meetings and a summary of topics covered.
You may also be interested in...
Inability to chew Arymo ER tablet helps Egalet overcome questions about clinical meaningfulness of human oral abuse study results; advisors also back intranasal, intravenous deterrence claims.
No device-related warning letters were released by the US FDA the week of 22 September.
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.